How Dexamethasone Used in Anti-COVID-19 Therapy Influenced Antihypertensive Treatment in Patients with SARS-CoV-2.

Autor:	Cârstea AP; Department of Physiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Cardiology, Clinical Municipal Hospital 'Philanthropy' of Craiova, 200143 Craiova, Romania., Mită A; Department of Medical Semiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Internal Medicine 2-Gastroenterology Compartment, 'Philanthropy' Clinical Municipal Hospital of Craiova, 200143 Craiova, Romania., Fortofoiu MC; Department of Medical Semiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Internal Medicine 2-Gastroenterology Compartment, 'Philanthropy' Clinical Municipal Hospital of Craiova, 200143 Craiova, Romania., Doica IP; Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania., Cârstea D; Department of Cardiology, Clinical Municipal Hospital 'Philanthropy' of Craiova, 200143 Craiova, Romania.; Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania., Beznă CM; Department of Cardiology, Clinical County Emergency Hospital of Craiova, 200642 Craiova, Romania., Negroiu CE; Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Cardiology, Clinical County Emergency Hospital of Craiova, 200642 Craiova, Romania., Diaconu ID; Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Pediatric Pneumology, National Institute of Pneumology 'Marius Nasta' of Bucharest, 050159 Bucharest, Romania., Georgescu AR; Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Emergency Medicine, Clinical County Emergency Hospital of Craiova, 200642 Craiova, Romania., Kamal AM; Department of Internal Medicine, Faculty of Midwives and General Nursing, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Internal Medicine 1, 'Philanthropy' Clinical Municipal Hospital of Craiova, 200143 Craiova, Romania., Mahler B; Department of Pneumology, University of Medicine and Pharmacy 'Carol Davila' Bucharest, 020021 Bucharest, Romania.; National Institute of Pneumophtisiology 'Marius Nasta', 050159 Bucharest, Romania., Grigorie AG; Department of Physiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Leamna Pneumophtisiology Hospital, Leamna de Sus, 207129 Dolj, Romania., Dobrinescu GA; Department of Thoracic Surgery, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.; Department of Thoracic Surgery, Clinical County Emergency Hospital of Craiova, 200642 Craiova, Romania.
Jazyk:	angličtina
Zdroj:	Healthcare (Basel, Switzerland) [Healthcare (Basel)] 2023 May 11; Vol. 11 (10). Date of Electronic Publication: 2023 May 11.
DOI:	10.3390/healthcare11101399
Abstrakt:	Background: During the SARS-CoV-2 pandemic period, in the treatment approved by the WHO, along with antivirals, antibiotics, nonsteroidal anti-inflammatory drugs and anticoagulants, dexamethasone was always used. This study started from the professional concern related to the vasopressor effect of cortisone on blood pressure (BP). Methods: The study group was achieved by selecting, from a total of 356 patients hospitalized in the clinic, the patients with known hypertensive status at admission for SARS-CoV-2. Dexamethasone was part of the anti-COVID-19 treatment, with an administration of 4-6-8 mg/day, depending on bodyweight, for 10 days. All patients with hypertension received antihypertensive treatment in adjusted doses according to the recorded BP values. Results: Monitoring of BP in hospitalized patients was performed daily, in the morning and evening. If on the 2nd day of treatment, 84% of the patients partially responded to the treatment with a moderate decrease in BP, on the 3rd therapy day, the situation clearly improved: more than 75% of the patients had values of BP that can be classified as high-normal (38.23%) and normal (40.03%). Conclusions: Dexamethasone for treatment of SARS-CoV-2 infection did not have a notable influence on increasing BP, because the doses were low-moderate and prescribed for a short time. Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu